Alzheon
Biotechnology company Alzheon develops treatments for neurodegenerative disorders, with a lead oral drug candidate, ALZ-801, for Alzheimer's disease.
Secondary Market Price
How Alzheon Measures Up
To help you manage your Alzheon equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Alzheon's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Alzheon Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Alzheon's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Alzheon, Inc. is a privately held biotechnology company founded in 2013 and headquartered in Framingham, MA. The company focuses on developing treatments for Alzheimer's disease and other neurodegenerative disorders. Its primary clinical candidate is ALZ-801, an oral small molecule designed to block the formation of neurotoxic amyloid oligomers in the brain. ALZ-801 is a prodrug of tramiprosate, a compound previously evaluated in trials involving over 2,000 Alzheimer's patients. Alzheon employs a precision medicine approach, using genetic and biological data to target therapies for specific patient populations.
The company is currently advancing ALZ-801 through late-stage clinical development, including the APOLLOE4 Phase 3 trial, which has shown cognitive and functional benefits in patients with mild cognitive impairment who are APOE ε4 homozygotes. In July 2024, Alzheon raised $100 million in a Series E funding round. Recent activities include the peer-reviewed publication of its Phase 3 trial results, presentations at industry conferences such as CTAD and AAIC, and the integration of AI technologies to improve data processing. The company is also expanding its pipeline with a backup portfolio of drug candidates.
- Alerce Medical Technology Partners
- Ally Bridge Group
- National Institute on Aging
- Scott H. Cohen
- Founder, Founder Martin Tolar
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Alzheon worth joining?
Deciding to join any startup involves evaluating many factors, including the potential of its equity compensation. Platforms like Prospect can help you model the future value of your equity to make a more informed career decision.
What should I do with my Alzheon stock?
Managing private company stock involves complex decisions around when to exercise options and how to plan for taxes. Using a tool like Prospect can provide you with a customized strategy for your shares based on your financial situation.
Can you sell Alzheon stock?
As Alzheon is a private company, selling stock is typically only possible during specific events like a tender offer or on a secondary marketplace. Prospect offers tools to help you navigate these opportunities and determine which shares are the most tax-optimal to sell.
How can I find the value of my Alzheon stock?
The value of private stock isn't publicly listed and is determined by internal 409A valuations and secondary market pricing. You can use Prospect's predictive models, which are trained on venture capital data, to forecast the potential future value of your equity.
What is Alzheon's equity worth?
The total worth of your equity depends on the company's valuation, which can be difficult to track for a private company. Platforms like Prospect use machine learning models to project your stock's value and help you create a strategy to maximize your net worth.
What is Alzheon's stock ticker symbol?
Since Alzheon is a private, pre-IPO company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they become publicly listed.
Can I buy or sell Alzheon stock?
As a private company, buying Alzheon stock is generally restricted to accredited investors or employees, while selling is limited to company-approved tender offers or secondary markets. If you are an employee with equity, Prospect provides tools to help you decide when and how much to sell during these limited opportunities.
What is the criteria to buy or invest in Alzheon stock?
Investing in a private company like Alzheon is typically limited to institutional investors, venture capital firms, and accredited investors who meet specific income or net worth requirements. Employees may also receive equity as part of their compensation, which they can manage using specialized tools.
